- About Us
- Nano-Social Network
- Nano Consulting
- My Account
May 1st, 2008
CytImmune Sciences, which is developing a nanotech treatment for cancer, will become the first industry ‘‘customer" to use the biomanufacturing facility at the University of Maryland Biotechnology Institute.
* Plans for new Adventist hospital move forward
* More unhappy returns on state school aid
* Faison has successful recipe at T.G.I. Friday's
* Gas prices create financial nightmare for trash operations
* Bethesda homeless find support from nonprofit
The Rockville facility was built in 2006 specifically to help small companies meet federal quality standards for their products.
CytImmune, with 16 employees, will partner with UMBI's ‘‘good manufacturing practices" facility to help develop AuriTol, which uses nanotechnology to target cancer, said Lawrence Tamarkin, CEO of the Rockville company.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017
Oxford Nanoimaging report on how the Nanoimager, a desktop microscope delivering single molecule, super-resolution performance, is being applied at the MRC Centre for Molecular Bacteriology & Infection November 22nd, 2016
New Agricultural Research Center Debuts at UCF October 12th, 2016
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017